"The voice for cancer physicians and their patients in Massachusetts."

  • 08 Jan 2018 2:32 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted regular approval to the anti-PD1 monoclonal antibody, nivolumab (Opdivo; Bristol-Myers Squibb) for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or in patients with metastatic disease who have undergone complete resection. Read full press release.

  • 08 Jan 2018 2:25 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug administration granted regular approval to pertuzumab (Perjeta; Genentech) for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. Read full press release.

  • 28 Nov 2017 9:43 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted regular approval to obinutuzumab (Gazyva; Genentech) in combination with chemotherapy, followed by obinutuzumab monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II buly; III, or IV follicular lymphoma (FL). Read full press release.

  • 17 Nov 2017 7:39 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved emicizumab-kxwh (Hemlibra; Genentech) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congential factor VIII deficiency) with factor VIII inhibitors. Read full press release. 

  • 16 Nov 2017 11:00 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted regular approval to brentuximab vedotin (Adcetris; Seattle Genomics) for the treatment of adult-patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systematic therapy. Read full press release. 

  • 16 Nov 2017 10:53 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted regular approval to dasatinib (Sprycel; Bristol-Myers Squibb) for the treatment of pediatric patients with Philadelphia chromosome-positive (PH+) chronic myeloid leukemia (CML) in the chronic phase. Read full press release.

  • 16 Nov 2017 10:46 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted regular approval to alectinib (Alecensa; Genentech) for the treatment of partients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. Read full press release. 

  • 28 Sep 2017 9:42 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved Mvasi (bevacizumab-awwb, Amgen) as a biosimilar to Avastin (bevacizumab, Genentech). Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer. Read full press release. 

  • 28 Sep 2017 9:31 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda; Merck) for patients with recurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 as determined by an FDA-approved test. Patients must have had disease progression on or after two or more prior systemic therapies, including fluoropyrimidine- and platinum- containing chemotherapy and, if appropriate, HER2/neu- targeted therapy. Read full press release. 

  • 25 Sep 2017 2:18 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted accelerated approval to nivolumab (Opdivo; Bristo-Myers Squibb) for the treatment of hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib. Read full press release. 

Upcoming events

  • No upcoming events

Massachusetts Society of Clinical Oncologists (c)

P.O. Box 549154, Waltham, MA, 02454
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software